Evidence map›Paper›PMID 41492093›Full record

Trial reportNature cancer2026

Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial.

Rebecca A Burrell, Sanjeev Kumar, Elena Provenzano, Cleopatra Pike, Alimu Dayimu, Stuart A McIntosh, Vassilis Pitsinis, Polly King, Beatrix Elsberger, Sasi Govindarajulu and 18 more

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Rebecca A Burrell *Cancer Research UK Cambridge Centre, Cambridge, UK.
Sanjeev Kumar *Cancer Research UK Cambridge Centre, Cambridge, UK.
Elena ProvenzanoNIHR Cambridge Biomedical Research Centre, Cambridge, UK.
Cleopatra PikeDepartment of Oncology, University of Cambridge, Cambridge, UK.
Alimu DayimuCambridge Clinical Trials Unit Cancer Theme, Cambridge, UK.ORCID http://orcid.org/0000-0001-9998-7463
Stuart A McIntoshPatrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.ORCID http://orcid.org/0000-0002-4123-9611
Vassilis PitsinisDepartment of Breast Surgery, Ninewells Hospital and Medical School, Dundee, UK.
Polly KingRoyal Cornwall Hospitals NHS Trust, Truro, UK.
Beatrix ElsbergerAberdeen Royal Infirmary/University of Aberdeen, Breast Unit, Aberdeen, UK.ORCID http://orcid.org/0000-0002-2864-5789
Sasi GovindarajuluSouthmead Hospital, North Bristol NHS Trust, Bristol, UK.
Lucy SatherleyCardiff University-Peking University Cancer Institute, Cardiff University School of Medicine, Cardiff, UK.
Sirwan HadadWomen's Health, University College London Hospitals NHS Foundation Trust, London, UK.
Peter SchmidBarts Cancer Institute, Queen Mary University of London, London, UK.
Amit AgrawalCambridge Breast Unit, Addenbrooke's Hospital, Cambridge, UK.ORCID http://orcid.org/0000-0002-3144-0493
Bodiere AkpulumaCancer Research UK Cambridge Centre, Cambridge, UK.
Steven BellCancer Research UK Cambridge Centre, Cambridge, UK.ORCID http://orcid.org/0000-0001-6774-3149
John R BensonCambridge Breast Unit, Addenbrooke's Hospital, Cambridge, UK.
Carlos CaldasCancer Research UK Cambridge Centre, Cambridge, UK.ORCID http://orcid.org/0000-0003-3547-1489
Danya CheesemanCancer Research UK Cambridge Institute, Cambridge, UK.
Igor ChernukhinCancer Research UK Cambridge Institute, Cambridge, UK.
Parto ForouhiCambridge Breast Unit, Addenbrooke's Hospital, Cambridge, UK.
Tulay GulsenCambridge Clinical Trials Unit Cancer Theme, Cambridge, UK.
Eleftheria KleidiCambridge Breast Unit, Addenbrooke's Hospital, Cambridge, UK.
Karen PinillaCancer Research UK Cambridge Centre, Cambridge, UK.ORCID http://orcid.org/0000-0002-2723-0805
Wendi QianCambridge Clinical Trials Unit Cancer Theme, Cambridge, UK.ORCID http://orcid.org/0000-0002-4238-3471
Jean E AbrahamCancer Research UK Cambridge Centre, Cambridge, UK.ORCID http://orcid.org/0000-0003-0688-4807
Jason S CarrollCancer Research UK Cambridge Institute, Cambridge, UK.
Richard D BairdCancer Research UK Cambridge Centre, Cambridge, UK. rdb39@cam.ac.uk.ORCID http://orcid.org/0000-0001-7071-6483

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of progestogens in breast cancer has been controversial. Recent preclinical studies have shown that ligand-bound progesterone receptor interacts directly with the estrogen receptor (ER) and reprograms ER transcriptional activity. Progestogen cotreatment enhances the antitumor activity of antiestrogen therapy in mouse xenografts. We report PIONEER, a 198-participant, three-arm, randomized phase 2b window-of-opportunity study for women with early-stage ER

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsReceptors, EstrogenReceptors, ProgesteroneAdultAgedCell ProliferationFemaleHumansLetrozoleMiddle AgedLetrozoleReceptors, EstrogenReceptors, Progesterone

Identifiers

PMID41492093
PMCPMC12858400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.